- Eli Lilly (NYSE:LLY) has hired an independent consultant to review a plant producing its promising COVID-19 antibody drug after receiving complaints from the FDA.
- The facility, located in Branchburg, New Jersey, had previously received an Official Action Indicated notice from the health regulator, resulting in the company halting the drug's Phase 3 trials.
- Details? Government documents seen by Reuters showed that inspectors who visited the Lilly plant in New Jersey last November found that data on the plant's various manufacturing processes had been deleted and not appropriately audited.
- https://seekingalpha.com/news/3624057-lilly-taps-outside-advisor-for-problems-covid-drug-plant
Wednesday, October 21, 2020
Lilly taps outside advisor for problems at COVID drug plant
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.